Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam
November 28, 2023 11:45 ET
|
Mithra Pharmaceuticals
Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam Five abstracts on the positive effect of E4 accepted for oral...
Mithra releases invitation to its extraordinary securities holders’ meeting
November 06, 2023 12:52 ET
|
Mithra Pharmaceuticals
Mithra releases invitation to its extraordinary securities holders’ meeting Liege, Belgium, 06 November 2023 – 17:45 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to...
Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreement
October 23, 2023 01:00 ET
|
Mithra Pharmaceuticals
Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreement Relates to the submission of a marketing approval application in JapanMarks strong...
Mithra Provides an Update in the Context of Recent Market Developments
October 05, 2023 01:00 ET
|
Mithra Pharmaceuticals
Mithra Provides an Update in the Context of Recent Market Developments Financial results show Mithra has solid financial foundation and multiple options to financeShareholder meetings called to...
Mithra présentera ses résultats financiers du premier semestre 2023 à ses investisseurs lors d'une conférence web le 26 septembre à 14 h 00 CET
September 22, 2023 07:30 ET
|
Mithra Pharmaceuticals
Mithra présentera ses résultats financiers du premier semestre 2023 à ses investisseurs lors d'une conférence web le 26 septembre à 14 h 00 CET Liège, Belgique, 22 septembre 2023 – 13 h 30 CET –...
Mithra to Hold Investor Call on H1 2023 Financial Results on September 26 at 14:00 CEST
September 21, 2023 11:55 ET
|
Mithra Pharmaceuticals
Mithra to Hold Investor Call on H1 2023 Financial Results on September 26 at 14:00 CEST Liege, Belgium, September 21, 2023 – 5:45 pm CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to...
Letter to Shareholders and Corporate Update
September 11, 2023 01:30 ET
|
Mithra Pharmaceuticals
Letter to Shareholders and Corporate Update Liege, Belgium, 11 September 2023 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, (the “Company” or “Mithra”),...
Mithra completes EUR 20 million private placement in equity. Update of total number of voting rights (denominator)
August 28, 2023 11:45 ET
|
Mithra Pharmaceuticals
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED...
Mithra Receives EUR 1.25 Million Milestone Payment from Fuji Pharma under Estelle® Licensing Agreement
August 03, 2023 01:30 ET
|
Mithra Pharmaceuticals
Mithra Receives EUR 1.25 Million Milestone Payment from Fuji Pharma under Estelle® Licensing Agreement Relates to completion of the interim clinical study reports of Phase 3 trials in patients...
Mithra and Searchlight Pharma Announce Donesta® Licensing Agreement for Canada
July 31, 2023 01:30 ET
|
Mithra Pharmaceuticals
Mithra and Searchlight Pharma Announce Donesta® Licensing Agreement for Canada Mithra to receive up to €17.05 million in licensing fees and regulatory and sales milestones, along with tiered...